According to latest research, the global Digital Pathology Market accounted for US$ 852.08 million in 2021 and is expected to hit US$ 1,892.40 million by 2028 to rise at an annual growth rate of 12.1% from 2021 to 2028. Technological advancement in digital pathology systems, growing preference of telepathology in remote areas, and digital pathology for cancer treatment are the critical factors aiding the market expansion.
Digital pathology is an image-based information platform that aids the management of information created from a digital slide. A digital slide picture file is then created, that enables the user for high resolution visualization, interpretation and image analysis of digital pathology slides. Furthermore, the advantages include digitization of the workflow, collecting, storing & sharing the patent’s data from remote places. In addition, to the advantages there few more benefits that aims lesser risks of losing, damaging of the specimens, zero cost of transportation and lesser period. The use of digital pathology is mainly done for the detection of cancer, due to the high-resolution results of the images analyzed for the diagnostics. The rise in the prevalence of the cancer across the world is a major key factor or the growth of digital pathology market in the coming future.
The advent of information technology (IT) in healthcare has enabled physicians to maintain optimal workflow and meet the frequently changing patient’s preferences. Leica Biosystems introduced a software that can share digital pathology images and case data with experts outside the IT network. Computerization, robotic light microscopy, multiple fiber-optic communications, digital imagery, whole-slide imaging (WSI), LIS/LIMS interface, and high-speed networking are among the modern technologies assisting the pathologists.
Request for sample copy @ https://www.theinsightpartners.com/sample/TIPHE100000855/
People staying in remote regions need to travel to the urban areas for diagnosis, treatment, and follow-up. Digital pathology helps bridge the gap between patients from remote areas and diagnostic centers by providing an adequate access to healthcare organizations. A digital pathology setup is easy to install in rural labs and hospitals. It serves the remote telecommunication consultation, primarily for diagnosis and treatment. Several hospitals, primary care providers, private clinics, and other medical institutions offer remote telepathology services. Such systems reduce costs, benefit the organizations, and ensure patient’s satisfaction.
Periodic diagnosis is the first step of every cancer treatment. Traditional pathological methods can only detect tumors but find it gruesome to share the case for second review. This discrepancy is eliminated by digital pathology system that offers in-depth analysis and diagnosis of tumors. It involves the scanning of conventional glass slides and digitally unifying successive images into a single large image conveying the information. Pathologists, after hovering over the picture, gets an integrated and comprehensive overview of every unique cancer condition. Thus, the demand for technical advent in cancer treatment with the aspects discussed above bolsters the global digital pathology market.
The report segmentation of Digital Pathology Market as follows:
Based on product, the market is categorized into scanner, software, communication, and storage. The scanner segment occupied 55.37% market share in 2021 with a revenue total of US$ 471.79 million. It is projected to be worth US$ 1,035.24 million by 2028 to grow at 12.3% CAGR during 2021–2028.
As per the application, the market domain is split into drug discovery, disease diagnostics, telepathology, and training & education. The drug discovery segment held 37.97% market share in 2021. It was evaluated at US$ 323.54 million in 2021 and is estimated to garner US$ 745.35 million by 2028, expanding at 12.7% CAGR along the forecast period.
Dominating players in the global digital pathology market are Koninklijke Philips N.V.; Nikon Corporation; Perkin Elmer, Inc; Indica Labs; 3DHISTECH Ltd; Danaher; Hamamatsu Photonics K.K.; F. Hoffmann-La Roche LTD; Visiopharm A/S; and Glencoe Software, Inc, among others.
• In March 2019, Nikon Instruments partnered with OptraSCAN to create an end-to-end digital pathology solution that combines Nikon’s leading optics with OptraSCAN’s well-established desktop slide scanning system, the OS-15.
• In October 2020, Indica Labs announced the formal launch of an enterprise-wide, cloud-based deployment of Indica Labs’ software within the National Cancer Institute (NCI). It facilitates the analysis of thousands of digital images daily.
• In December 2019, 3DHISTECH introduced the hardware upgrade of PANNORAMIC MIDI II, the best-selling, award-winning member of its digital whole-slide scanner range.